Core Viewpoint - The company, Bibet (688759.SH), has received approval from the National Medical Products Administration (NMPA) to conduct I-II phase clinical trials for its innovative siRNA drug, BEBT-701, aimed at treating mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol (LDL-C) levels [1][2]. Group 1: Company Developments - BEBT-701 is the first drug developed using the company's proprietary GalNAc dual oligonucleotide conjugate (GDOC) technology platform, designed to silence two key targets, angiotensinogen (AGT) and proprotein convertase subtilisin/kexin type 9 (PCSK9), simultaneously [1]. - The drug aims to provide a long-acting, low-frequency administration solution for managing chronic diseases, improving adherence among high cardiovascular risk populations [1]. Group 2: Clinical and Non-Clinical Research - Non-clinical studies have demonstrated that BEBT-701 achieves efficient and durable gene silencing of AGT and PCSK9 in humanized mouse models and non-human primates, showing synergistic effects in lowering blood pressure and cholesterol levels with good safety profiles [1]. - The World Health Organization's Global Hypertension Report indicates that approximately 1.4 billion people worldwide suffer from hypertension, with around 245 million adults affected in China, highlighting the significant market potential for effective treatments [2]. Group 3: Industry Context - The use of siRNA drugs, such as BEBT-701, represents a shift towards low-frequency, precise, and stable management of cardiovascular metabolic diseases, addressing issues related to long-term medication adherence and fluctuations in drug concentration [2].

Core Viewpoint - The company, Bibet (688759.SH), has received approval from the National Medical Products Administration (NMPA) to conduct I-II phase clinical trials for its innovative siRNA drug, BEBT-701, aimed at treating mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol (LDL-C) [1][2] Group 1: Company Developments - BEBT-701 is the first drug developed using the company's proprietary GalNAc dual oligonucleotide conjugate (GDOC) technology platform, designed to silence two key targets, AGT and PCSK9, simultaneously [1] - The drug aims to provide a long-acting, low-frequency administration solution for managing chronic diseases in high cardiovascular risk populations by improving both blood pressure and lipid levels [1] - Non-clinical studies have shown that BEBT-701 effectively and durably silences AGT and PCSK9 in humanized mouse models and non-human primates, demonstrating synergistic effects in lowering blood pressure and lipids with good safety profiles [1] Group 2: Industry Context - According to the World Health Organization's Global Hypertension Report, approximately 1.4 billion people worldwide are affected by hypertension, with around 245 million adults in China suffering from the condition [2] - Hypertension often coexists with high LDL-C, posing significant risks for cardiovascular diseases [2] - siRNA drugs, like BEBT-701, offer a new pathway for managing cardiovascular metabolic diseases by enabling low-frequency, precise, and stable control of treatment, addressing issues related to long-term medication adherence and drug concentration fluctuations [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for its innovative drug BEBT-701, which targets both AGT and PCSK9 for the treatment of mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol [1] Group 1 - The drug BEBT-701 is a globally first-of-its-kind small interfering RNA (siRNA) medication [1] - The approval allows the company to initiate Phase I-II clinical trials for BEBT-701 [1] - The development of the drug involves a lengthy research cycle, multiple approval stages, and significant investment, leading to various uncertainties [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for its innovative drug BEBT-701, which targets both AGT and PCSK9 for the treatment of mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol [1] Group 1 - The drug BEBT-701 is a globally first-of-its-kind small interfering RNA (siRNA) medication [1] - The approval allows the company to initiate Phase I-II clinical trials for BEBT-701 [1] - The targeted condition for the drug includes mild to moderate hypertension along with elevated low-density lipoprotein cholesterol [1]

Group 1 - The core point of the news is that Bibet has experienced a significant decline in its stock price, dropping 5.01% on February 2, with a total market value of 18.249 billion yuan and a cumulative decline of 22.17% over four consecutive days [1] - Bibet is a pharmaceutical company based in Guangzhou, established on January 19, 2012, and focuses on the independent research and development of innovative drugs [1] - The stock trading volume on February 2 was 62.963 million yuan, with a turnover rate of 3.27% [1] Group 2 - From the perspective of major fund holdings, one fund under China Merchants Fund has a significant position in Bibet, with the China Merchants CSI Robot ETF holding 2,789 shares, accounting for 0.0051% of the circulating shares [2] - The fund has incurred a floating loss of approximately 5,968.46 yuan today, with a total floating loss of 33,900 yuan during the four-day decline [2] - The China Merchants CSI Robot ETF was established on January 19, 2024, with a current scale of 309 million yuan and a year-to-date return of 4.39% [2]

Core Viewpoint - Guangzhou Bibete Pharmaceutical Co., Ltd. has completed the registration change and received a new business license following the approval of changes to its registered capital, company type, and amendments to its articles of association [1]. Group 1: Company Changes - The company held its second board meeting on November 11, 2025, and the first extraordinary general meeting of shareholders on November 28, 2025, to approve the proposal for changes in registered capital and company type [1]. - The company has received a new business license from the Huangpu District Market Supervision Administration of Guangzhou, reflecting the changes made [1]. Group 2: Company Information - The updated business license indicates the following details: - Unified Social Credit Code: 91440101589519277H - Name: Guangzhou Bibete Pharmaceutical Co., Ltd. - Type: Joint-stock company (foreign investment, listed) - Address: 25 A-3 Building, Yaying Stone Road, Science City, High-tech Industrial Development Zone, Guangzhou - Legal Representative: Qian Changgeng - Registered Capital: 450,366,570 RMB - Establishment Date: January 19, 2012 - Business Scope: Research and experimental development [1].

证券日报网讯 1月29日，必贝特发布公告称，近期公司完成了变更登记及备案，并收到了广州市黄埔区 市场监督管理局换发的《营业执照》。 （文章来源：证券日报） ...

证券代码：688759 证券简称：必贝特 公告编号：2026-003 广州必贝特医药股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州必贝特医药股份有限公司（以下简称"公司"）于 2025 年 11 月 11 日 召开第二届董事会第七次（临时）会议及 2025 年 11 月 28 日召开的 2025 年第一 次临时股东大会审议通过了《关于变更公司注册资本、公司类型、修订<公司章 程>并办理工商变更登记的议案》。具体内容详见公司于 2025 年 11 月 13 日在上 海证券交易所网站（www.sse.com.cn）披露的《广州必贝特医药股份有限公司关 于变更公司注册资本、公司类型、修订<公司章程>并办理工商变更登记的公告》 （公告编号：2025-005）。 类型：股份有限公司（外商投资、上市） 住所：广州市高新技术产业开发区科学城崖鹰石路 25 号 A-3 栋第八层 802 房 法定代表人：钱长庚 QIAN CHANGGENG 注册资本：肆亿伍仟零叁万陆仟陆佰伍拾柒 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300436 | 广生堂 | 105.01 | 14.00% | 21.58万 | | 22.03亿 | | 300765 | 新诺威 | 46.21 | 12.90% | 23.06万 | | 10.27亿 | | 688428 | 诺诚健华 | 20.39 | 2.05% | 6.96万 | | 1.41亿 | | 300401 | 化园生物 | 17.71 | 1.84% | P 29.42万 | | 5.24亿 | | 688192 | 迪哲医药 | 58.96 | 1.78% | 2.60万 | | 1.52亿 | | 002099 | 海翔药业 | 6.35 | 1.28% | 33.69万 | | 2.14亿 | | 688578 | 文力斯 | 101.30 | 1.25% | 4.40万 | | 4.40 乙 | | 300573 | 兴齐眼药 | 72.10 | 1.22% | 8.25万 | | 5.96亿 | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 【导读】震荡上涨 中国基金报记者 泰勒 兄弟姐妹们啊，回顾一下今天市场发生了什么事情吧。 1月28日，市场全天震荡，截至收盘，沪指涨0.27%，深成指涨0.09%，创业板指跌0.57%。 两市共1739只个股上涨，84只个股涨停，3640只个股下跌。 | 880005 张跌家数 | | | | | --- | --- | --- | --- | | 日中 | 涨停 | | 84 | | 涨幅 | > 7% | | 169 | | 涨幅 | 5-7% | 1 | 105 | | 涨幅 | 3-5% | | 252 | | 张唱 | 0-3% | | 1213 | | 跌幅 | 0-3% | | 2912 | | 跌幅 | 3-5% | | 258 | | 跌幅 | 5-7% | | 112 | | 跌幅 | > 7% | | 58 | | 其中 跌停 | | | 28 | | 上涨家数 | | | 1739 | | 下跌家药 | | | 3640 | | 平盘停牌 当日种数 | | | ae | | | | | 5475 | | 总成交额 ...